<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="description" content="drugdevelopR">
<title>Multitrial Programs - Methods for Programs with Several Phase III Trials • drugdevelopR</title>
<script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="../deps/bootstrap-5.2.2/bootstrap.min.css" rel="stylesheet">
<script src="../deps/bootstrap-5.2.2/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous">
<!-- bootstrap-toc --><script src="https://cdn.jsdelivr.net/gh/afeld/bootstrap-toc@v1.0.1/dist/bootstrap-toc.min.js" integrity="sha256-4veVQbu7//Lk5TSmc7YV48MxtMy98e26cf5MrgZYnwo=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Multitrial Programs - Methods for Programs with Several Phase III Trials">
<meta property="og:description" content="drugdevelopR">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">drugdevelopR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.1.0</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto">
<li class="nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="active nav-item dropdown">
  <a href="#" class="nav-link dropdown-toggle" data-bs-toggle="dropdown" role="button" aria-expanded="false" aria-haspopup="true" id="dropdown-articles">Articles</a>
  <div class="dropdown-menu" aria-labelledby="dropdown-articles">
    <a class="dropdown-item" href="../articles/Bias_adjustment.html">Methods for Discounting of Phase II Results - Bias Adjustment</a>
    <a class="dropdown-item" href="../articles/Binary_distributed_outcomes.html">Binary Distributed Outcome Variables</a>
    <a class="dropdown-item" href="../articles/Fixed_and_prior_distributions.html">Fixed effects and prior distributions</a>
    <a class="dropdown-item" href="../articles/Interpreting_Output.html">Interpreting the Rest of the Output</a>
    <a class="dropdown-item" href="../articles/More_Parameters.html">More Parameters to Adapt to Specific Settings and Individual Needs</a>
    <a class="dropdown-item" href="../articles/Multiarm_Trials.html">Multiarm - Methods for Multi-Arm Programs</a>
    <a class="dropdown-item" href="../articles/Multiple_Endpoints.html">Multiple_Endpoints</a>
    <a class="dropdown-item" href="../articles/Multitrial.html">Multitrial Programs - Methods for Programs with Several Phase III Trials</a>
    <a class="dropdown-item" href="../articles/Time-to-event_outcomes.html">Time-to-event Outcome Variables</a>
    <a class="dropdown-item" href="../articles/introduction-to-drugdevelopR.html">Introduction to planning phase II and phase III trials with drugdevelopR</a>
  </div>
</li>
<li class="nav-item">
  <a class="nav-link" href="../news/index.html">Changelog</a>
</li>
      </ul>
<form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off">
</form>

      <ul class="navbar-nav">
<li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/Sterniii3/drugdevelopR/" aria-label="github">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul>
</div>

    
  </div>
</nav><div class="container template-article">




<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="" class="logo" alt=""><h1>Multitrial Programs - Methods for Programs with Several Phase III Trials</h1>
            
      
      <small class="dont-index">Source: <a href="https://github.com/Sterniii3/drugdevelopR/blob/HEAD/vignettes/Multitrial.Rmd" class="external-link"><code>vignettes/Multitrial.Rmd</code></a></small>
      <div class="d-none name"><code>Multitrial.Rmd</code></div>
    </div>

    
    
<p>Suppose we are planning a drug development program testing the
superiority of an experimental treatment over a control treatment. Our
drug development program consists of an exploratory phase II trial which
is, in case of promising results, followed by a confirmatory phase III
trial.</p>
<p>The drugdevelopR package enables us to optimally plan such programs
using a utility-maximizing approach. To get a brief introduction, we
presented a very basic example on how the package works in <a href="https://sterniii3.github.io/drugdevelopR/articles/introduction-to-drugdevelopR.html">Introduction
to planning phase II and phase III trials with drugdevelopR</a>.
Contrary to the basic setting, where only one phase III trial was
conducted, we now want to show how several phase III trials can be
included within the framework.</p>
<div class="section level2">
<h2 id="the-example-setting">The example setting<a class="anchor" aria-label="anchor" href="#the-example-setting"></a>
</h2>
<p>Suppose we are developing a new tumor treatment, <em>exper</em>. The
patient variable that we want to investigate is how long the patient
survives without further progression of the tumor (progression free
survival). This is a time to event outcome variable. Therefore, we will
use the function <code>optimal_multitrial</code>, which calculates
optimal sample sizes and threshold decisions values for time-to-event
outcomes when several phase III trials are performed.</p>
<p>Within our drug development program, we will compare our experimental
treatment <em>exper</em> to the control treatment <em>contro</em>. The
treatment effect measure is given by <span class="math inline">\(\theta
= −\log(HR)\)</span>, which is the negative logarithm of the hazard
ratio <span class="math inline">\(HR\)</span>, which is the ratio of the
hazard rates. If we assume that unfavorable events as tumor progression
occur only 75% as often as in the control group, we have a hazard ratio
of 0.75.</p>
</div>
<div class="section level2">
<h2 id="applying-the-package-to-the-example">Applying the package to the example<a class="anchor" aria-label="anchor" href="#applying-the-package-to-the-example"></a>
</h2>
<p>After installing the package according to the <a href="https://sterniii3.github.io/drugdevelopR/#Installation">installation
instructions</a>, we can load it using the following code:</p>
<div class="sourceCode" id="cb1"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="kw"><a href="https://rdrr.io/r/base/library.html" class="external-link">library</a></span><span class="op">(</span><span class="va"><a href="https://github.com/Sterniii3/drugdevelopR" class="external-link">drugdevelopR</a></span><span class="op">)</span></span>
<span><span class="co">#&gt; Loading required package: mvtnorm</span></span>
<span><span class="co">#&gt; Loading required package: doParallel</span></span>
<span><span class="co">#&gt; Loading required package: foreach</span></span>
<span><span class="co">#&gt; Loading required package: iterators</span></span>
<span><span class="co">#&gt; Loading required package: parallel</span></span>
<span><span class="co">#&gt; Loading required package: msm</span></span>
<span><span class="co">#&gt; Loading required package: cubature</span></span></code></pre></div>
<p>We insert the same input values as in the example for time-to-event
outcomes (see the vignette on <a href="https://sterniii3.github.io/drugdevelopR/articles/Time-to-event_outcomes.html">time-to-event
endpoints</a>). As in the basic setting, the treatment effect may be
fixed (as in this example) or follows a prior distribution (see <a href="https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html">Fixed
or Prior</a>). Furthermore, some options to adapt the program to your
specific needs are also available in this setting (see <a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html">More
Paramters</a>), however skipping phase II, setting predefined benefit
categories and choosing different treatment effects in phase II and III
are not possible.</p>
<p>The program implements a framework developed for phase II/III drug
development programs where several phase III trials are performed. This
is of particular relevance as regulatory agencies often require
statistical significance in two or more phase III trials. Different
cases, defined by the number of significant trials needed for approval,
should be implemented in the package. For each case, different
strategies, defined by the number of phase III trials to be conducted in
order to reach the goal of the case, should be implemented. For the
success of the drug development program, it is necessary that the
treatment effects of all phase III trials point in the same direction.
For example, if we select case 3 and strategy 4, we require four phase
III trials, where three need to be significant at level <span class="math inline">\(\alpha\)</span> and the treatment effect of the
fourth must point in the same direction. Hence, in addition to the
parameters from the basic setting, the user should be allowed to provide
the following parameters:</p>
<ul>
<li>A parameter to set the strategy,</li>
<li>A parameter to set the case.</li>
</ul>
<p>The following cases and possible strategies are implemented in the
program.</p>
<table class="table">
<colgroup>
<col width="8%">
<col width="91%">
</colgroup>
<thead><tr class="header">
<th>Case</th>
<th>Possible strategies for this case</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>1, 2</td>
</tr>
<tr class="even">
<td>2</td>
<td>1 (with significance level of <span class="math inline">\(\alpha^2\)</span>)* , 2, 3, 23 (=2+1)**</td>
</tr>
<tr class="odd">
<td>3</td>
<td>1 (with significance level of <span class="math inline">\(\alpha^3\)</span>)*, 3, 4</td>
</tr>
</tbody>
</table>
<p>*For cases 2 and 3, the package also provides the strategy to only
use one trial, but with adjusted significance level. This is included as
there is discussion that a larger trial with adjusted significance level
may also may serve evidence on efficacy (see Koch (2005)).</p>
<p>** For case 2, the package also provides a 2+1 one strategy: If after
conducting two trials, only one delivers a significant result and the
other trial’s treatment effect points at least in the same direction, a
third trial is conducted. This strategy is called “23” in the
package.</p>
<p>So, in addition to the parameters from the basic setting, we provide
the following parameters:</p>
<ul>
<li>The parameter <code>case</code> allows us to chose the number of
trials in phase III, that have to show a significant positive treatment
effect in order for the overall program to deemed successful. We
implemented the cases 1, 2 and 3 in the program, so one can set the
parameter to one of these values. In the following example we set the
parameter <code>case = 3</code>, indicating that at least two trials in
phase III have to show a significant treatment effect in phase III.</li>
<li>The parameter <code>strategy</code> amounts for the number of trials
that are conducted in phase III. We implemented the strategies 1, 2, 3
and 4, so programs with up to four trials can be evaluated within the
drugdevelopR framework. Furthermore, setting
<code>strategy = TRUE</code> returns the results of the optimization for
all implemented strategies for a specific case. Note, that not all
strategies are implemented for each case. All possible case-strategy
combinations can be seen in the table above. There are two special
combinations, which are implemented. Setting <code>strategy = 23</code>
in case 2 leads to the situation where two phase III trials are
conducted. If only one shows a significant positive treatment effect
(and the other trial’s treatment effect points at least in the same
direction) a third trial is conducted. Furthermore, setting
<code>strategy = 1</code> in cases 2 and 3 leads to a situation where
one large phase III trial is conducted with adjusted significance level,
i.e. <span class="math inline">\(\alpha_{new} = \alpha^2\)</span> in
case 2 and <span class="math inline">\(\alpha_{new} = \alpha^3\)</span>
in case 3. Note, that setting <code>case = 1</code> and
<code>strategy = 1</code> leads to the same results as in the basic
setting, i.e. one phase III trial, that has to show a significant
positive treatment effect. For the following example we set
<code>strategy = TRUE</code>.</li>
</ul>
<p>Note, that for the following example, same input parameters where
changed compared to the basic setting in order to reduce computation
time.</p>
<div class="sourceCode" id="cb2"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb2-1"><a href="#cb2-1" aria-hidden="true" tabindex="-1"></a>res1 <span class="ot">&lt;-</span> <span class="fu">optimal_multitrial</span>(<span class="at">w =</span> <span class="fl">0.3</span>,                       <span class="co"># define parameters for prior</span></span>
<span id="cb2-2"><a href="#cb2-2" aria-hidden="true" tabindex="-1"></a>   <span class="at">hr1 =</span> <span class="fl">0.7</span>, <span class="at">hr2 =</span> <span class="fl">0.8</span>, <span class="at">id1 =</span> <span class="dv">210</span>, <span class="at">id2 =</span> <span class="dv">420</span>,            <span class="co"># (https://web.imbi.uni-heidelberg.de/prior/)</span></span>
<span id="cb2-3"><a href="#cb2-3" aria-hidden="true" tabindex="-1"></a>   <span class="at">d2min =</span> <span class="dv">20</span>, <span class="at">d2max =</span> <span class="dv">200</span>, <span class="at">stepd2 =</span> <span class="dv">5</span>,                   <span class="co"># define optimization set for d2</span></span>
<span id="cb2-4"><a href="#cb2-4" aria-hidden="true" tabindex="-1"></a>   <span class="at">hrgomin =</span> <span class="fl">0.7</span>, <span class="at">hrgomax =</span> <span class="fl">0.9</span>, <span class="at">stephrgo =</span> <span class="fl">0.02</span>,         <span class="co"># define optimization set for HRgo</span></span>
<span id="cb2-5"><a href="#cb2-5" aria-hidden="true" tabindex="-1"></a>   <span class="at">alpha =</span> <span class="fl">0.05</span>, <span class="at">beta =</span> <span class="fl">0.1</span>, <span class="at">xi2 =</span> <span class="fl">0.7</span>, <span class="at">xi3 =</span> <span class="fl">0.7</span>,        <span class="co"># drug development planning parameters</span></span>
<span id="cb2-6"><a href="#cb2-6" aria-hidden="true" tabindex="-1"></a>   <span class="at">c2 =</span> <span class="fl">0.75</span>, <span class="at">c3 =</span> <span class="dv">1</span>, <span class="at">c02 =</span> <span class="dv">100</span>, <span class="at">c03 =</span> <span class="dv">150</span>,               <span class="co"># define fixed and variable costs</span></span>
<span id="cb2-7"><a href="#cb2-7" aria-hidden="true" tabindex="-1"></a>   <span class="at">K =</span> <span class="cn">Inf</span>, <span class="at">N =</span> <span class="cn">Inf</span>, <span class="at">S =</span> <span class="sc">-</span><span class="cn">Inf</span>,                            <span class="co"># set constraints</span></span>
<span id="cb2-8"><a href="#cb2-8" aria-hidden="true" tabindex="-1"></a>   <span class="at">b1 =</span> <span class="dv">1000</span>, <span class="at">b2 =</span> <span class="dv">2000</span>, <span class="at">b3 =</span> <span class="dv">3000</span>,                       <span class="co"># define expected benefits</span></span>
<span id="cb2-9"><a href="#cb2-9" aria-hidden="true" tabindex="-1"></a>   <span class="at">fixed =</span> <span class="cn">TRUE</span>,                                          <span class="co"># choose if  effects are fixed or random</span></span>
<span id="cb2-10"><a href="#cb2-10" aria-hidden="true" tabindex="-1"></a>   <span class="at">case =</span> <span class="dv">3</span>, <span class="at">strategy =</span> <span class="cn">TRUE</span>                              <span class="co"># choose case and strategy</span></span>
<span id="cb2-11"><a href="#cb2-11" aria-hidden="true" tabindex="-1"></a>   <span class="at">num_cl =</span> <span class="dv">3</span>)</span></code></pre></div>
<div class="section level3">
<h3 id="interpreting-the-output">Interpreting the output<a class="anchor" aria-label="anchor" href="#interpreting-the-output"></a>
</h3>
<p>After setting all these input parameters and running the function,
let’s take a look at the output of the program.</p>
<div class="sourceCode" id="cb3"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="va">res1</span></span>
<span><span class="co">#&gt;   Case Strategy       u HRgo  d2  d3   d  n2  n3   n  pgo sProg  hr   K   N</span></span>
<span><span class="co">#&gt; 1    3        1  -64.48 0.78 105 444 549 150 634 784 0.71  0.45 0.7 Inf Inf</span></span>
<span><span class="co">#&gt; 2    3        3 -272.50 0.78  75 417 492 108 594 702 0.68  0.32 0.7 Inf Inf</span></span>
<span><span class="co">#&gt; 3    3        4 -293.81 0.70  60 264 324  86 376 462 0.50  0.25 0.7 Inf Inf</span></span>
<span><span class="co">#&gt;      S  K2  K3 sProg1 sProg2 sProg3 steps1 stepm1 stepl1    alpha beta xi2 xi3</span></span>
<span><span class="co">#&gt; 1 -Inf 212 741   0.10   0.25   0.10      1   0.95   0.85 0.000125  0.1 0.7 0.7</span></span>
<span><span class="co">#&gt; 2 -Inf 181 900   0.01   0.13   0.18      1   0.95   0.85 0.050000  0.1 0.7 0.7</span></span>
<span><span class="co">#&gt; 3 -Inf 164 676   0.00   0.20   0.05      1   0.95   0.85 0.050000  0.1 0.7 0.7</span></span>
<span><span class="co">#&gt;   c02 c03   c2 c3   b1   b2   b3 gamma</span></span>
<span><span class="co">#&gt; 1 100 150 0.75  1 1000 2000 3000     0</span></span>
<span><span class="co">#&gt; 2 100 150 0.75  1 1000 2000 3000     0</span></span>
<span><span class="co">#&gt; 3 100 150 0.75  1 1000 2000 3000     0</span></span></code></pre></div>
<p>The program returns a data frame, where the output for all
implemented strategies is listed. For strategy 1 we get:</p>
<ul>
<li>
<code>res$d2</code> is the optimal number of events for phase II and
<code>res$d3</code> the resulting number of events for phase III. We see
that the optimal scenario requires 105 events in phase II and 444 events
in phase III, which correspond to 150 participants in phase II and 634
in phase III.</li>
<li>
<code>res$HRgo</code> is the optimal threshold value for the
go/no-go decision rule. We see that we need a hazard ratio of less than
0.78 in phase II in order to proceed to phase III.</li>
<li>
<code>res$u</code> is the expected utility of the program for the
optimal sample size and threshold value. In our case it amounts to
-64.48, i.e we have an expected utility of -6 448 000$. Note, that the
input parameter <code>alpha</code> is returned having a value of
0.000125, which corresponds to the adjusted significance level <span class="math inline">\(\alpha^3\)</span>.</li>
</ul>
<p>The results for strategy 3 are:</p>
<ul>
<li>
<code>res$d2</code> is the optimal number of events for phase II and
<code>res$d3</code> the resulting number of events for phase III. We see
that the optimal scenario requires 75 events in phase II and 417 events
in phase III, which leads to 108 participants in phase II and 594 in
phase III. This corresponds to three trials in phase III with each trial
having 298 participants.</li>
<li>
<code>res$HRgo</code> is the optimal threshold value for the
go/no-go decision rule. We see that we need a hazard ratio of less than
0.78 in phase II in order to proceed to phase III.</li>
<li>
<code>res$u</code> is the expected utility of the program for the
optimal sample size and threshold value. In our case it amounts to
-272.50, i.e we have an expected utility of -27 250 000$.</li>
</ul>
<p>Strategy 4 yields the following results:</p>
<ul>
<li>
<code>res$d2</code> is the optimal number of events for phase II and
<code>res$d3</code> the resulting number of events for phase III. We see
that the optimal scenario requires 60 events in phase II and 264 events
in phase III, which leads to 86 participants in phase II and 376 in
phase III. This corresponds to four trials in phase III with each trial
having 94 participants.</li>
<li>
<code>res$HRgo</code> is the optimal threshold value for the
go/no-go decision rule. We see that we need a hazard ratio of less than
0.70 in phase II in order to proceed to phase III.</li>
<li>
<code>res$u</code> is the expected utility of the program for the
optimal sample size and threshold value. In our case it amounts to
-293.81, i.e we have an expected utility of -29 381 000$.</li>
</ul>
</div>
</div>
<div class="section level2">
<h2 id="where-to-go-from-here">Where to go from here<a class="anchor" aria-label="anchor" href="#where-to-go-from-here"></a>
</h2>
<p>In this article we presented an example when several phase III
endpoints are performed. Note, that this example is not restricted to
time-to-event endpoints but can also be applied to binary and normally
distributed endpoints by using the functions
<code>optimal_multitrial_binary</code> and
<code>optimal_multitrial_normal</code>. For more information on how to
use the package, see:</p>
<ul>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/introduction-to-drugdevelopR.html"><em>Introduction
to drugdevelopR:</em></a> See how the package works in a basic
example.</li>
<li>
<em>Different outcomes:</em> Apply it to <a href="https://sterniii3.github.io/drugdevelopR/articles/Binary_distributed_outcomes.html">binary
endpoints</a> and <a href="https://sterniii3.github.io/drugdevelopR/articles/Time-to-event_outcomes.html">time-to-event
endpoints</a>.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/Interpreting_Output.html"><em>Interpreting
the rest of the output:</em></a> Obtain further details on your drug
development program.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html"><em>Fixed
or prior:</em></a> Model the assumed treatment effect on a prior
distribution.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html"><em>More
parameters:</em></a> Define custom effect size categories. Put
constraints on the optimization by defining maximum costs, the total
expected sample size of the program or the minimum expected probability
of a successful program. Define an expected difference in treatment
effect between phase II and III. Skip phase II.</li>
<li>
<em>Complex drug development programs:</em> Adapt to situations with
<a href="https://sterniii3.github.io/drugdevelopR/articles/Bias_adjustment.html">biased
effect estimators</a>, <a href="https://sterniii3.github.io/drugdevelopR/articles/Multiarm_Trials.html">multi-arm
trials</a>, or multiple endpoints.</li>
<li>
<em>Parallel computing:</em> Be faster at calculating the optimum by
using parallel computing.</li>
</ul>
</div>
<div class="section level2">
<h2 id="references">References<a class="anchor" aria-label="anchor" href="#references"></a>
</h2>
<p>Koch, G. G. (2005). Statistical consideration of the strategy for
demon- strating clinical evidence of effectiveness one larger vs two
smaller pivotal studies by z. shun, e. chi, s. durrleman and l. fisher,
statistics in medicine 2005; 24: 1619–1637. Statistics in Medicine,
24(11):1639–1646.</p>
</div>
  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside>
</div>



    <footer><div class="pkgdown-footer-left">
  <p></p>
<p>Developed by Stella Preussler.</p>
</div>

<div class="pkgdown-footer-right">
  <p></p>
<p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.7.</p>
</div>

    </footer>
</div>

  

  

  </body>
</html>
